Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00040170 · ClinicalTrials.gov registry record · Phase 2
Vaccine Study of MVA-MUC1-IL2 in Patients With Prostate Cancer
A Phase 2 study, sponsored by Transgene.
- Terminated
- Registry status
- Phase 2
- Development phase
- 50
- Enrollment target
NCT00040170 is a Phase 2 study that was terminated before completion, run by Transgene. The registered enrollment target is 50 participants.
The verdict
NCT00040170, a Phase 2 study, was terminated before completion, sponsored by Transgene.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 50 participants
- Enrollment target
Study Summary
This study involves the use of an experimental product, TG4010. The purpose of the study is to determine if TG4010 can stimulate the body's immune system to help it fight the cancer.
Interventions
- BIOLOGICAL MVA-MUC1-IL2
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2002-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00040170
The ClinicalTrials.gov registry entry for NCT00040170 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Transgene, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which MVA-MUC1-IL2 is the first listed.
NCT00040170 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00040170 about?
NCT00040170 is a clinical study titled "Vaccine Study of MVA-MUC1-IL2 in Patients With Prostate Cancer". This study involves the use of an experimental product, TG4010. The purpose of the study is to determine if TG4010 can stimulate the body's immune system to help it fight the cancer.
What is the current status of trial NCT00040170?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 50 participants. The study started on 2002-05.
What interventions are being tested in trial NCT00040170?
The interventions under investigation include: MVA-MUC1-IL2 (BIOLOGICAL).
Who is sponsoring clinical trial NCT00040170?
This trial is sponsored by Transgene, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.